Immunoprotein Diagnostic Testing - Market Insights, Competitive Landscape, and Market Forecast - 2034

Published Date : 2026
Pages : 150
Region : Global,
Delivery Timeline : 24 Hours

Immunoprotein Diagnostic Testing Market Summary

  • The Immunoprotein Diagnostic Testing market size is estimated at USD 2.6 billion in 2025 and is projected to reach USD 4.6 billion by 2034. Growth is anchored in the rising burden of inflammatory, autoimmune, and immune disorders, the growth of C-reactive protein and specific protein testing, and increasing automation of immunoprotein assays on clinical laboratory analyzers.
  • The global Immunoprotein Diagnostic Testing market is growing at a CAGR of 6.5% during the forecast period from 2026 to 2034.
  • By product, the reagents and assay kits segment dominated the Immunoprotein Diagnostic Testing market with a 65% share in 2025.
  • By technology, the nephelometry segment dominated the Immunoprotein Diagnostic Testing market with a share of 30% in 2025.
  • By application, the inflammatory conditions segment dominated the Immunoprotein Diagnostic Testing market with a share of 26% in 2025.
  • By end-user, the hospitals segment dominated the Immunoprotein Diagnostic Testing market with a share of 44% in 2025.
  • North America dominated the global Immunoprotein Diagnostic Testing market revenue with a share of 38% in 2025, representing the highest regional market share globally.

Immunoprotein diagnostic testing comprises the assays, reagents, kits, and instruments used to measure specific proteins in blood, urine, and other body fluids to support the diagnosis and monitoring of inflammatory, immune, autoimmune, renal, cardiovascular, nutritional, and hematological conditions. Measured immunoproteins include C-reactive protein, immunoglobulins, complement components, serum free light chains, acute phase proteins, and specific proteins such as albumin, transferrin, haptoglobin, ceruloplasmin, alpha-1 antitrypsin, and beta-2 microglobulin. Testing is performed using nephelometry, immunoturbidimetry, enzyme-linked immunosorbent assay, chemiluminescence immunoassay, and electrophoresis and immunofixation, supplied by companies such as Siemens Healthineers through its BN and Atellica systems, Roche, Abbott, Danaher through Beckman Coulter, and Thermo Fisher Scientific through The Binding Site with the Freelite free light chain assays, along with Bio-Rad, DiaSorin, Werfen, Sebia, and QuidelOrtho. Testing is performed in hospitals, diagnostic and reference laboratories, academic and research institutes, and other settings. Over the past decade, the field has advanced with the integration of immunoprotein assays onto high-throughput automated analyzers, the growth of serum free light chain testing for monoclonal gammopathies, and the expansion of C-reactive protein and specific protein testing. Driven by the rising burden of inflammatory and immune disorders and the growth of specific protein testing, immunoprotein diagnostic testing is an important and steadily growing segment of the in vitro diagnostics market.

Immunoprotein Diagnostic Testing Market Key Growth Drivers

  • The rising global burden of inflammatory, autoimmune, and immune disorders is expanding demand for immunoprotein testing to support diagnosis and monitoring.
  • The widespread and growing use of C-reactive protein testing, including high-sensitivity and point-of-care testing, is driving high-volume immunoprotein testing.
  • The growing diagnosis and monitoring of multiple myeloma and monoclonal gammopathies is expanding serum free light chain and immunoglobulin testing.
  • The increasing automation and integration of immunoprotein assays onto high-throughput clinical chemistry and immunoassay analyzers are improving throughput and access.
  • The aging population and rising burden of chronic disease are increasing the demand for immunoprotein testing across multiple conditions.
  • Expanding healthcare access and laboratory infrastructure in emerging markets are broadening the global demand for immunoprotein diagnostic testing.
  • The convergence of rising immune and inflammatory disease burden, specific protein testing growth, and laboratory automation is expected to sustain steady growth in the global Immunoprotein Diagnostic Testing market through 2034.

Key Companies in Immunoprotein Diagnostic Testing Market

The competitive landscape is led by the following active developers and manufacturers of immunoprotein diagnostic testing reagents, kits, and instruments:

  • Siemens Healthineers AG
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • DiaSorin S.p.A.
  • Werfen, S.A.
  • Sebia S.A.
  • QuidelOrtho Corporation, and others

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

Immunoprotein Diagnostic Testing Market Size

The following snapshot summarizes the principal report metrics for the Immunoprotein Diagnostic Testing market.

Report Metrics

Details

2025 Market Size

USD 2.6 billion

2034 Projected Market Size

USD 4.6 billion

Growth Rate (2026-2034)

6.5% CAGR

Largest Market

North America

Fastest Growing Market

Asia-Pacific

Market Structure

Consolidated

All market values are expressed in USD and represent DelveInsight estimates synthesized from primary and secondary research.

Factors Contributing to the Growth of the Immunoprotein Diagnostic Testing Market

Immunoprotein Diagnostic Testing Market Drivers

  • Rising Burden of Inflammatory, Autoimmune, and Immune Disorders: The rising global burden of inflammatory, autoimmune, and immune disorders is the foundational driver of immunoprotein diagnostic testing demand. Immunoprotein testing, including C-reactive protein, immunoglobulins, complement, and specific proteins, is central to the diagnosis, assessment, and monitoring of inflammation, infection, autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, and immunodeficiency disorders. The rising prevalence of these conditions, driven by aging, environmental, and lifestyle factors, expands the population requiring testing, and the chronic nature of many of these diseases generates recurring monitoring. Immunoprotein markers are widely used in initial evaluation, differential diagnosis, and disease monitoring across many conditions. As the burden of inflammatory and immune disorders continues to rise worldwide, demand for immunoprotein testing continues to grow, reinforcing sustained market growth throughout the forecast period.
  • Widespread and Growing Use of C-Reactive Protein Testing: The widespread and growing use of C-reactive protein testing is a powerful driver of the immunoprotein diagnostic testing market. C-reactive protein is one of the most frequently ordered laboratory tests worldwide, used as a marker of inflammation and infection across countless clinical scenarios, and high-sensitivity C-reactive protein is used in cardiovascular risk assessment. The growth of point-of-care C-reactive protein testing, particularly to guide antibiotic prescribing and support antimicrobial stewardship in primary care and acute settings, is expanding testing volumes and access. C-reactive protein assays are available across nephelometry, turbidimetry, and point-of-care platforms from all major manufacturers, generating very high test volumes. As C-reactive protein testing continues to expand across clinical and point-of-care settings, it is expected to be a significant driver of immunoprotein testing volume across the forecast period.
  • Growing Diagnosis and Monitoring of Monoclonal Gammopathies: The growing diagnosis and monitoring of multiple myeloma and monoclonal gammopathies is a defining driver of the immunoprotein diagnostic testing market. Serum free light chain testing, immunoglobulin quantification, and electrophoresis and immunofixation are central to the diagnosis, risk stratification, and monitoring of multiple myeloma, monoclonal gammopathy of undetermined significance, amyloidosis, and related conditions. The Freelite serum free light chain assay from The Binding Site, now part of Thermo Fisher Scientific, and the N Latex free light chain assay from Siemens Healthineers are widely used, and guidelines recommend free light chain testing in the workup and monitoring of these conditions. The rising diagnosis of multiple myeloma, an increasingly treatable cancer with a growing prevalence as survival improves, expands testing. As the diagnosis and long-term monitoring of monoclonal gammopathies continue to grow, serum free light chain and immunoglobulin testing is expected to be an important driver of market growth across the forecast period.
  • Increasing Automation and Integration on Laboratory Analyzers: The increasing automation and integration of immunoprotein assays onto high-throughput clinical laboratory analyzers is a substantial driver of the market. Many immunoprotein assays, historically performed on dedicated nephelometry systems, are increasingly available as immunoturbidimetric assays integrated onto high-throughput clinical chemistry and immunoassay analyzers, such as Siemens Healthineers' Atellica, Roche's cobas, Abbott's Alinity, and Beckman Coulter systems, improving throughput, efficiency, and access. Automation and consolidation of testing onto integrated platforms reduce cost and turnaround time and support rising test volumes, while dedicated nephelometry systems such as Siemens' BN systems remain important for specialized and specific protein testing. This automation expands the accessibility and volume of immunoprotein testing. As laboratories continue to automate and integrate immunoprotein testing onto high-throughput platforms, this trend is expected to be an important driver of market growth across the forecast period.
  • Aging Population and Rising Chronic Disease Burden: The aging global population and rising burden of chronic disease are powerful drivers of immunoprotein testing demand. Older adults carry a higher prevalence of inflammatory, autoimmune, renal, cardiovascular, and hematological conditions, including multiple myeloma and monoclonal gammopathies, that require immunoprotein testing, and the number of older people is rising rapidly worldwide. The rising prevalence of chronic diseases across all age groups, including cardiovascular and kidney disease that involve specific protein testing such as high-sensitivity C-reactive protein and urine albumin, further expands testing. The chronic nature of these conditions generates recurring monitoring. As populations age and the burden of chronic disease rises, demographic and epidemiological trends are expected to be a significant driver of immunoprotein testing demand across the forecast period.
  • Expanding Healthcare Access and Laboratory Infrastructure in Emerging Markets: Expanding healthcare access and laboratory infrastructure, particularly in emerging markets, is opening significant growth opportunities. Rising incomes, growing insurance coverage, and investment in healthcare and laboratory capacity across Asia-Pacific, Latin America, the Middle East, and Africa are increasing access to immunoprotein testing. Growing awareness, improving diagnosis rates, and the expansion of laboratory services and automated analyzers broaden demand, and point-of-care testing expands access in decentralized settings. Both multinational and regional manufacturers are expanding their presence, automated platforms, and reagent menus. Government and private investment in diagnostic capacity further supports growth. As healthcare access expands and laboratory capacity grows in emerging economies, this expansion is expected to be an important driver of immunoprotein diagnostic testing market growth across the forecast period.

Immunoprotein Diagnostic Testing Market Restraints

Despite steady momentum, the Immunoprotein Diagnostic Testing market faces material constraints. The high capital cost of automated nephelometry and immunoassay analyzers limits adoption among smaller laboratories, and the need for instrument placement, service, and validation adds operational burden. Reimbursement and cost-containment pressures constrain testing volumes and the adoption of newer or specialized assays in some settings, and many immunoprotein tests carry modest reimbursement. Test standardization and harmonization remain challenges for certain immunoproteins, including differences between nephelometric and turbidimetric methods and between free light chain assays, which can complicate result comparison and monitoring. Competition and commoditization of high-volume assays such as C-reactive protein compress prices. A shortage of trained laboratory personnel can constrain capacity, and the interpretation of some immunoprotein results requires specialized expertise. Rigorous and evolving regulatory requirements for in vitro diagnostic devices, including the European In Vitro Diagnostic Regulation and Food and Drug Administration pathways, add cost and complexity to product development and market entry. Finally, uneven laboratory infrastructure and affordability constraints in emerging markets can restrict access and adoption across parts of the forecast period.

Immunoprotein Diagnostic Testing Market Segment Analysis

The Immunoprotein Diagnostic Testing Market is segmented by product (reagents and assay kits, analyzers and instruments, software and services), technology (nephelometry, immunoturbidimetry, enzyme-linked immunosorbent assay, chemiluminescence immunoassay, electrophoresis and immunofixation, others), application (inflammatory conditions, autoimmune diseases, immunodeficiency disorders, renal disorders, cardiovascular disease, oncology and monoclonal gammopathies, others), end-user (hospitals, diagnostic and reference laboratories, academic and research institutes, others), and geography (North America, Europe, Asia-Pacific, Rest of World).

By Product

Dominant Subsegment: Reagents and Assay Kits.

The reagents and assay kits segment accounted for 65% of the Immunoprotein Diagnostic Testing market in 2025. Reagents and assay kits dominate because immunoprotein testing is a high-volume, recurring-use field in which every test consumes assay-specific antibodies, reagents, calibrators, and controls for C-reactive protein, immunoglobulins, complement, free light chains, and specific proteins. The very high volumes of routine tests such as C-reactive protein and immunoglobulins, together with growing free light chain and specific protein testing, generate steady, per-test demand that far exceeds one-time instrument purchases in aggregate revenue. Leading suppliers such as Siemens Healthineers, Roche, Abbott, Beckman Coulter, and Thermo Fisher through The Binding Site generate substantial recurring reagent revenue, underpinning the razor-and-blade model of the industry. The analyzers and instruments segment, including nephelometry systems, integrated chemistry and immunoassay analyzers, and point-of-care devices, represents important capital revenue and anchors reagent pull-through, and software and services is a smaller supporting segment. Nonetheless, the continuous, volume-driven consumption of reagents and assay kits, tied directly to testing volume, secures the segment's leadership across the forecast period.

By Technology

Dominant Subsegment: Nephelometry.

The nephelometry segment accounted for 30% of the Immunoprotein Diagnostic Testing market in 2025. Nephelometry dominates because it is the established reference technology for the quantification of many immunoproteins, including immunoglobulins, complement, specific proteins, and serum free light chains, offering high sensitivity and precision on dedicated systems such as Siemens Healthineers' BN systems and Beckman Coulter's IMMAGE. Nephelometry is widely used in specialized and specific protein testing and remains central to free light chain and immunoglobulin measurement. Immunoturbidimetry is a large and growing technology, as many immunoprotein assays, including C-reactive protein and immunoglobulins, are increasingly performed as turbidimetric assays integrated onto high-throughput clinical chemistry analyzers, improving throughput and access. Enzyme-linked immunosorbent assay and chemiluminescence immunoassay serve many specific protein and specialized tests, and electrophoresis and immunofixation are essential for the characterization of monoclonal proteins in gammopathies, supported by companies such as Sebia and Helena. Nonetheless, the sensitivity, precision, and established role of nephelometry in specific protein and free light chain testing secure its leadership across the forecast period, with immunoturbidimetry growing rapidly through integration onto automated analyzers.

By Application

Dominant Subsegment: Inflammatory Conditions.

The inflammatory conditions segment accounted for 26% of the Immunoprotein Diagnostic Testing market in 2025. Inflammatory conditions dominate because C-reactive protein and other inflammatory markers are among the most frequently ordered laboratory tests worldwide, used across infection, inflammation, and a vast range of clinical scenarios, and increasingly at the point of care to guide antibiotic use. The extremely high volume of C-reactive protein and related inflammatory testing drives the largest share of immunoprotein testing. Autoimmune diseases represent a large application, using immunoglobulin, complement, and specific protein testing in the workup and monitoring of conditions such as rheumatoid arthritis and lupus, and oncology and monoclonal gammopathies represent a large and growing application driven by serum free light chain, immunoglobulin, and electrophoresis testing for multiple myeloma and related conditions. Immunodeficiency disorders, renal disorders, cardiovascular disease, and other applications add substantial demand. Nonetheless, the very high volume of inflammatory marker testing, led by C-reactive protein, secures the leadership of the inflammatory conditions segment across the forecast period.

By End-User

Dominant Subsegment: Hospitals.

The hospitals segment accounted for 44% of the Immunoprotein Diagnostic Testing market in 2025. Hospitals dominate because they perform high volumes of immunoprotein testing for the diagnosis and monitoring of acute and chronic conditions, including inflammation, infection, autoimmune disease, and monoclonal gammopathies, and they operate the central laboratories and automated analyzers that run these assays. The concentration of acute care, complex diagnosis, and inpatient and outpatient testing in hospitals drives the largest share of immunoprotein testing, and hospitals are major purchasers of nephelometry and integrated analyzers. Diagnostic and reference laboratories represent a large and growing end user, performing high-volume routine and specialized immunoprotein testing on a centralized basis, benefiting from automation and economies of scale, and receiving referred and esoteric testing such as free light chain and electrophoresis. Academic and research institutes and other settings, including point-of-care and primary care for C-reactive protein testing, add further demand. Nonetheless, the concentration of high-volume and complex immunoprotein testing in hospitals secures the leadership of the hospitals segment across the forecast period, with diagnostic and reference laboratories growing through centralization.

Immunoprotein Diagnostic Testing Market Region Analysis

North America accounted for 38% of the global Immunoprotein Diagnostic Testing market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects advanced laboratory infrastructure, high testing volumes, rapid adoption of automated and specialized immunoprotein testing, and the presence of leading manufacturers. The United States leads on the strength of a large hospital and reference laboratory network, high volumes of C-reactive protein, immunoglobulin, and free light chain testing, rapid adoption of automated analyzers and point-of-care testing, and the presence of major players including Abbott, Beckman Coulter through Danaher, Thermo Fisher through The Binding Site, and QuidelOrtho. Disease burden is substantial, with a large population affected by inflammatory, autoimmune, cardiovascular, and hematological conditions. The regulatory environment is well established, with the Food and Drug Administration providing clearance pathways for in vitro diagnostic devices. Reimbursement supports laboratory testing, and strong research infrastructure and laboratory investment further reinforce the market. This combination of infrastructure, testing volume, and technology adoption reinforces North America's leadership in the global market.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Immunoprotein Diagnostic Testing market. The region's elevated CAGR is driven by large populations, a rising burden of inflammatory, autoimmune, and chronic disease, expanding healthcare access, and growing laboratory infrastructure across China, India, Japan, South Korea, and Southeast Asia. Rising diagnosis and testing rates, growing healthcare investment, and expanding insurance coverage are increasing access to immunoprotein testing, and improving laboratory capacity and automation are broadening access. China and India are expanding domestic diagnostic manufacturing and laboratory networks, and rising incomes and awareness are increasing testing demand, including point-of-care C-reactive protein testing. Both multinational and regional manufacturers are expanding their presence and automated and value-tier offerings. Government and private investment in diagnostic capacity further supports growth. The combination of large populations, rising disease burden, expanding access, and growing laboratory infrastructure positions Asia-Pacific as the highest-growth region over the forecast period.

Immunoprotein Diagnostic Testing Market Regional Commentary

North America

North America accounted for 38% of the global Immunoprotein Diagnostic Testing market revenue in 2025. The United States dominates the region on the strength of advanced laboratory infrastructure, high testing volumes, rapid adoption of automated and specialized testing, and the presence of leading manufacturers, while Canada contributes through its public laboratory networks and Mexico expands access within its growing healthcare sector.

Europe

Europe represents the second-largest regional market, led by Germany, France, and the United Kingdom. Growth is supported by established laboratory networks, high testing volumes, and the presence of major manufacturers such as Siemens Healthineers, Roche, DiaSorin, Werfen, and Sebia, while the European In Vitro Diagnostic Regulation shapes product requirements and market access across the region.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by large populations, a rising burden of inflammatory and chronic disease, expanding healthcare access, and growing laboratory infrastructure across China, India, Japan, South Korea, and Southeast Asia. Expanding domestic manufacturing, automation, and point-of-care testing are broadening access and adoption.

Rest of World

The Rest of World region, spanning the Middle East, Africa, and South America, is an emerging growth frontier. A rising burden of inflammatory and chronic disease, improving laboratory capacity, and expanding healthcare access are broadening adoption, while point-of-care testing and investment in diagnostic infrastructure support growth.

Immunoprotein Diagnostic Testing Market Competitive Landscape

The Immunoprotein Diagnostic Testing market is classified as Consolidated. A group of large diagnostics companies holds the majority of revenue through broad reagent, kit, and instrument portfolios, led by Siemens Healthineers, Roche, Abbott, and Danaher through Beckman Coulter, with Thermo Fisher through The Binding Site holding a leading position in free light chain testing, while Bio-Rad, DiaSorin, Werfen, Sebia, and QuidelOrtho hold significant positions, and a field of specialized and regional players competes across the market. The competitive landscape can be evaluated across the following dimensions:

  • Market concentration: Consolidated, with revenue concentrated among a few large diagnostics companies alongside specialized specific-protein and electrophoresis players.
  • Leading players: Siemens Healthineers, Roche, Abbott, and Danaher through Beckman Coulter anchor the top tier, with Thermo Fisher through The Binding Site leading free light chain testing and Bio-Rad, DiaSorin, Werfen, Sebia, and QuidelOrtho holding significant positions.
  • Geographic reach: Leaders operate global commercial, manufacturing, and support networks, with strong positions across North America, Europe, and Asia-Pacific.
  • Product portfolio strength: Top players hold broad portfolios spanning nephelometry, immunoturbidimetry, immunoassay, and electrophoresis, and extensive immunoprotein menus.
  • Pipeline strength: Deep pipelines in automated and integrated immunoprotein testing, free light chain and specific protein assays, and point-of-care testing.
  • Strategic partnerships: Collaborations with hospitals, reference laboratories, and health systems, and menu and platform partnerships, shape the competitive landscape.
  • M&A activity: Consolidation continues, exemplified by Thermo Fisher Scientific's acquisition of The Binding Site, a leader in free light chain testing.
  • Manufacturing capabilities: Large-scale reagent and antibody manufacturing and instrument production are key competitive strengths and barriers to entry.
  • Innovation focus: Automated and integrated immunoprotein testing, free light chain and specific protein assays, point-of-care C-reactive protein testing, and mass spectrometry for monoclonal proteins.

Immunoprotein Diagnostic Testing Market Recent Developmental Activities

  • In 2023, Thermo Fisher Scientific completed its acquisition of The Binding Site, a leader in serum free light chain testing with the Freelite assay. Strategic significance: Strengthens Thermo Fisher's position in specialty immunoprotein testing for monoclonal gammopathies.
  • In 2023 and 2024, Siemens Healthineers expanded its plasma protein and specific protein testing menus across its BN nephelometry and Atellica analyzer platforms. Strategic significance: Reinforces Siemens' leadership in nephelometry and integrated immunoprotein testing.
  • In 2023 and 2024, manufacturers expanded immunoturbidimetric immunoprotein assays integrated onto high-throughput clinical chemistry analyzers, including Roche cobas, Abbott Alinity, and Beckman Coulter systems. Strategic significance: Improves throughput, efficiency, and access for high-volume immunoprotein testing.
  • In 2023 and 2024, point-of-care C-reactive protein testing expanded to support antibiotic stewardship and rapid decision-making in primary and acute care. Strategic significance: Expands decentralized immunoprotein testing and supports appropriate antibiotic use.
  • In 2023 and 2024, serum free light chain testing expanded in the diagnosis and monitoring of multiple myeloma and monoclonal gammopathies, supported by Freelite and N Latex free light chain assays. Strategic significance: Reinforces specialty immunoprotein testing tied to a growing hematologic oncology population.
  • In 2023 and 2024, Sebia and other companies advanced electrophoresis and immunofixation systems and mass spectrometry approaches for the characterization of monoclonal proteins. Strategic significance: Advances the diagnosis and monitoring of monoclonal gammopathies.
  • In 2023 and 2024, high-sensitivity C-reactive protein testing continued to be used in cardiovascular risk assessment. Strategic significance: Sustains high-volume immunoprotein testing in cardiovascular applications.
  • In 2023 and 2024, laboratory automation and consolidation of immunoprotein testing onto integrated platforms expanded to address rising volumes and workforce constraints. Strategic significance: Improves efficiency and standardization and supports centralization of testing.
  • In 2023 and 2024, DiaSorin, Werfen, and other companies expanded specialty and specific protein testing menus. Strategic significance: Broadens the availability of specialized immunoprotein assays.
  • In 2023 and 2024, the European In Vitro Diagnostic Regulation continued to reshape requirements and market access for in vitro diagnostic devices in Europe. Strategic significance: Raises compliance requirements and influences portfolio and market-entry strategies.
  • In 2023 and 2024, regional manufacturers in Asia expanded immunoprotein testing reagents, kits, and automated platforms. Strategic significance: Broadens access in high-growth emerging markets and intensifies competition.
  • In 2023 and 2024, companies advanced connectivity and data solutions for immunoprotein testing to support integrated laboratory workflows. Strategic significance: Improves efficiency and integration of immunoprotein testing in laboratories.

Immunoprotein Diagnostic Testing Market Segmentation

  • Immunoprotein Diagnostic Testing Market by Product
    • Reagents and Assay Kits
    • Analyzers and Instruments
    • Software and Services
  • Immunoprotein Diagnostic Testing Market by Technology
    • Nephelometry
    • Immunoturbidimetry
    • Enzyme-Linked Immunosorbent Assay
    • Chemiluminescence Immunoassay
    • Electrophoresis and Immunofixation
    • Others
  • Immunoprotein Diagnostic Testing Market by Application
    • Inflammatory Conditions
    • Autoimmune Diseases
    • Immunodeficiency Disorders
    • Renal Disorders
    • Cardiovascular Disease
    • Oncology and Monoclonal Gammopathies
    • Others
  • Immunoprotein Diagnostic Testing Market by End-User
    • Hospitals
    • Diagnostic and Reference Laboratories
    • Academic and Research Institutes
    • Others

Immunoprotein Diagnostic Testing Market Assessment by Geography

  • North America Immunoprotein Diagnostic Testing Market Assessment
    • United States Immunoprotein Diagnostic Testing Market Size in USD million (2023-2034)
    • Canada Immunoprotein Diagnostic Testing Market Size in USD million (2023-2034)
    • Mexico Immunoprotein Diagnostic Testing Market Size in USD million (2023-2034)
  • Europe Immunoprotein Diagnostic Testing Market Assessment
    • Germany Immunoprotein Diagnostic Testing Market Size in USD million (2023-2034)
    • United Kingdom Immunoprotein Diagnostic Testing Market Size in USD million (2023-2034)
    • France Immunoprotein Diagnostic Testing Market Size in USD million (2023-2034)
    • Italy Immunoprotein Diagnostic Testing Market Size in USD million (2023-2034)
    • Spain Immunoprotein Diagnostic Testing Market Size in USD million (2023-2034)
    • Rest of Europe Immunoprotein Diagnostic Testing Market Size in USD million (2023-2034)
  • Asia-Pacific Immunoprotein Diagnostic Testing Market Assessment
    • China Immunoprotein Diagnostic Testing Market Size in USD million (2023-2034)
    • Japan Immunoprotein Diagnostic Testing Market Size in USD million (2023-2034)
    • India Immunoprotein Diagnostic Testing Market Size in USD million (2023-2034)
    • Australia Immunoprotein Diagnostic Testing Market Size in USD million (2023-2034)
    • South Korea Immunoprotein Diagnostic Testing Market Size in USD million (2023-2034)
    • Rest of Asia-Pacific Immunoprotein Diagnostic Testing Market Size in USD million (2023-2034)
  • Rest of the World (RoW) Immunoprotein Diagnostic Testing Market Assessment
    • Middle East Immunoprotein Diagnostic Testing Market Size in USD million (2023-2034)
    • Africa Immunoprotein Diagnostic Testing Market Size in USD million (2023-2034)
    • South America Immunoprotein Diagnostic Testing Market Size in USD million (2023-2034)

Immunoprotein Diagnostic Testing Market Recent Industry Trends and Milestones (2023-2026):

Category

Key Developments

Immunoprotein Diagnostic Testing Market Product Approval

Manufacturers secured FDA clearances and CE markings for immunoprotein assays and analyzers; free light chain, specific protein, and C-reactive protein assays expanded across platforms; the European In Vitro Diagnostic Regulation continued to reshape in vitro diagnostic requirements.

Immunoprotein Diagnostic Testing Market Product Expansion

Siemens Healthineers expanded BN and Atellica plasma protein menus; Roche, Abbott, and Beckman Coulter expanded immunoturbidimetric assays on integrated analyzers; Thermo Fisher through The Binding Site advanced free light chain testing; Sebia advanced electrophoresis and immunofixation; point-of-care C-reactive protein testing expanded.

Immunoprotein Diagnostic Testing Market Product Investment

Thermo Fisher Scientific acquired The Binding Site, a leader in free light chain testing; companies invested in automated and integrated immunoprotein testing, specialty assays, point-of-care testing, and mass spectrometry for monoclonal proteins; regional manufacturers invested in value-tier offerings.

Immunoprotein Diagnostic Testing Market Company Strategy

Siemens Healthineers AG: Nephelometry and integrated plasma protein testing. F. Hoffmann-La Roche Ltd, Abbott Laboratories, and Danaher Corporation: Integrated immunoturbidimetric testing. Thermo Fisher Scientific Inc.: Free light chain testing through The Binding Site. Bio-Rad, DiaSorin, Werfen, Sebia, and QuidelOrtho: Specialty, specific protein, and electrophoresis testing.

Immunoprotein Diagnostic Testing Market Emerging Technologies

Automated and integrated immunoprotein testing on high-throughput analyzers; free light chain and specific protein assays; point-of-care C-reactive protein testing for antibiotic stewardship; mass spectrometry for the characterization and monitoring of monoclonal proteins; and connected, automated laboratory workflows.

Immunoprotein Diagnostic Testing Market Startup Funding and Investment Trends

Investment in the immunoprotein and specific protein testing ecosystem has concentrated on point-of-care and decentralized immunoassay, rapid inflammation testing, and novel protein biomarkers. The following companies illustrate recent activity and technology focus.

Company

Total Funding

Funding Stage

Main Product

Core Technology

Lumos Diagnostics Holdings Ltd.

Public and venture funding

Public / growth-stage

Point-of-care inflammation and infection tests

Rapid point-of-care immunoassay including C-reactive protein and host-response markers

SpinChip Diagnostics ASA

Venture funding

Growth-stage venture

Point-of-care immunoassay platform

Microfluidic centrifugal point-of-care immunoassay for protein biomarkers

 

Request to unlock the report on the @ Immunoprotein Diagnostic Testing Market Insights

 

Lumos Diagnostics is developing rapid point-of-care tests for inflammation and infection, including C-reactive protein and host-response markers to guide antibiotic use, while SpinChip Diagnostics develops a microfluidic point-of-care immunoassay platform for protein biomarkers. Additional capital continues to flow toward point-of-care and decentralized immunoassay, rapid inflammation testing, and novel protein biomarkers, reflecting conviction that faster, more accessible, and decentralized protein testing is the next source of competitive advantage. Collectively, these efforts signal sustained investment in expanding access to immunoprotein testing, supporting antibiotic stewardship, and addressing inflammatory and immune conditions.

Key Takeaways from the Immunoprotein Diagnostic Testing Market Report Study

  • Market size analysis for the current immunoprotein diagnostic testing market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
  • Key companies dominating the global immunoprotein diagnostic testing market.
  • Various opportunities available for competitors in the immunoprotein diagnostic testing market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current immunoprotein diagnostic testing market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for immunoprotein diagnostic testing market growth in the future?

Target audience who can benefit from this immunoprotein diagnostic testing market report study

  • Immunoprotein Diagnostic Testing product providers
  • Research organizations and consulting companies
  • Immunoprotein Diagnostic Testing-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in immunoprotein diagnostic testing products
  • Various end-users who want to know more about the immunoprotein diagnostic testing market and the latest technological developments in the immunoprotein diagnostic testing market.

Frequently Asked Questions

Q1. What is the growth rate of the Immunoprotein Diagnostic Testing market?

The Immunoprotein Diagnostic Testing market is projected to expand at a CAGR of 6.5% during the forecast period of 2026-2034.

Q2. What is the market size of the Immunoprotein Diagnostic Testing market?

The Immunoprotein Diagnostic Testing market size is estimated at USD 2.6 billion in 2025 and is projected to reach USD 4.6 billion by 2034.

Q3. Which region dominates the Immunoprotein Diagnostic Testing market?

North America dominated the Immunoprotein Diagnostic Testing market with a 38% share of global revenue in 2025, supported by advanced laboratory infrastructure, high testing volumes, rapid adoption of automated and specialized testing, supportive FDA pathways, and the presence of leading manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Immunoprotein Diagnostic Testing market?

The principal drivers are the rising burden of inflammatory, autoimmune, and immune disorders; the widespread and growing use of C-reactive protein testing, including point-of-care testing; the growing diagnosis and monitoring of multiple myeloma and monoclonal gammopathies driving free light chain testing; and the increasing automation and integration of immunoprotein assays onto laboratory analyzers, reinforced by an aging population and expanding access in emerging markets.

Q5. Who are the major players in the Immunoprotein Diagnostic Testing market?

The major Immunoprotein Diagnostic Testing companies in the market include Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., DiaSorin S.p.A., Werfen, S.A., Sebia S.A., and QuidelOrtho Corporation, among other active manufacturers profiled in the Competitive Landscape section. Siemens Healthineers leads in nephelometry, and Thermo Fisher, through The Binding Site, leads in free light chain testing.

Tags:

  • Immunoprotein Diagnostic Testing
  • Immunoprotein Diagnostic Testing Mechanism
  • Immunoprotein Diagnostic Testing Companies
  • Immunoprotein Diagnostic Testing Medical devices

License Type


Offer

Request Sample

View Pricing

Customize Reports As Per Your Needs

Don't see what you're looking for? Get a report tailored to your specific requirements. Customize your report now!

Have a Question?

We are happy to assist you.

DelveInsight
DelveInsight
SUBSCRIPTION
Platform

Register for free trial today and gain instant access to 7000+ market
research reports